Neuropeptide Y-induced potentiation of noradrenergic vasoconstriction in the human saphenous vein: Involvement of endothelium generated thromboxane

British Journal of Pharmacology

Volumn 124, Issue 1, 1998, Pages 101-110

  Fabi, Fulvia ^b   Argiolas, Livio ^b   Ruvolo, Giovanni ^a   Del Basso, Paola ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cyclo oxygenase; Endothelium; Human saphenous veins; Neuropeptide Y; Sympathetic neurotransmission; Thromboxane

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ARACHIDONIC ACID; ARGININE; BOSENTAN; DAZMEGREL; ENDOTHELIN; IFETROBAN; INDOMETACIN; NEUROPEPTIDE Y; NITRIC OXIDE; NORADRENALIN; PROSTAGLANDIN SYNTHASE; RAMATROBAN; THROMBOXANE; THROMBOXANE A2; VASOACTIVE AGENT;

ARACHIDONIC ACID METABOLISM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; NERVE STIMULATION; PRIORITY JOURNAL; SAPHENOUS VEIN; SYMPATHETIC NERVE; SYMPATHETIC TONE; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; DRUG SYNERGISM; ELECTRIC STIMULATION; ENDOTHELIUM, VASCULAR; HUMANS; NEUROPEPTIDE Y; NITRIC OXIDE; NOREPINEPHRINE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SAPHENOUS VEIN; THROMBOXANE A2; VASOCONSTRICTOR AGENTS;

EID: 0031943157     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701808     Document Type: Article

References (50)

1. ADAMSSON, M., FALLGREN, B. & EDVINSSON, L. (1992). Inhibition of neuropeptide Y-induced potentiation of noradrenatine-induced vasoconstriction by PP56 (D-myo-inositol 1,2,6-trisphosphate). Br. J. Pharmacol., 105, 93-96.
2. AKSOY, M.O., HARAKAL, C., SMITH, J.B., STEWART, G.J. & ZERWECK, C.R. (1990). Mediation of bradykinin-induced contraction in canine veins via thromboxane/prostaglandin endoperoxide receptor activation. Br. J. Pharmacol., 99, 461 466.
3. ALDASORO, M., MARTINEZ, C., VILA, J.M., FLOR, B. & LLUCH, S. (1993). Endothelium-dependent component in the contractile responses of human omental arteries to adrenergic stimulation. Eur. J. Pharmacol., 250, 103 107.
4. 2. J. Pharmacol. Exp. Ther., 236, 535-541.
5. ANDRIANTSITOHAINA, R. & STOCLET, J.C. (1988). Potentiation by neuropeptide Y of vasoconstriction in rat resistance arteries. Br. J. Pharmacol., 95, 419 428.
6. ANDRIANTSITOHAINA, R., ANDRE, P. & STOCLET, J.C. (1990). Pertussis toxin abolishes the effect of neuropeptide Y on rat resistance arteriole contraction. Am. J. Physiol., 259, H1427-H1432.
7. ANDRIANTSITOHAINA, R., BIAN, K., STOCLET, J.C. & BUKOSKI, R.D. (1993). Neuropeptide Y increases force development through a mechanism that involves calcium entry in resistance arteries. J. Vasc. Res., 30, 309 314.
8. BUDAI, D., VU, H.Q. & DUCKLES, S.P. (1989). Endothelium removal does not affect potentiation by neuropeptide Y in rabbit ear artery. Eur. J. Pharmacol., 168, 97-100.
9. 2. Circ. Res., 72, 1023-1034.
10. 2 receptors. J. Pharmacol. Exp. Ther., 268, 902-909.
11. 2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries. Circulation, 87, 874 880.
12. CLOZEL, M., BREU, V., GRAY, G.A., KALINA, B., LOFFLER, B.M., BURRI, K., CASSAL, J.M., HIRT, G., MULLER, M., NEIDHART, W. & RAMUZ, H. (1994). Pharmacological characterization of Bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther., 270, 228-235.
13. 2-receptor agonist. U46619. Br. J. Pharmacol., 110, 360-368.
14. DALY, R.N. & HIEBLE, J.P. (1987). Neuropeptide Y modulates adrenergic neurotransmission by an endothelium dependent mechanism. Eur. J. Pharmacol., 138, 445-446.
15. DESCOMBES, J.-J., DEVYS, M., LAUBIE, M. & VERBEUREN, T.J. (1993). Endothelial thromboxane production plays a role in the contraction caused by 5-hydroxytryptamine in rat basilar arteries. Eur. J. Pharmacol., 243, 193-199.
16. DUCKLES, S.P. & BUXTON, I.L.O. (1994). Neuropeptide Y potentiates norepinephrine-stimulated inositol phosphate production in the rat tail artery. Life Sci., 55, 103 109.
17. EDVINSSON, L., EKBLAD, E., HAKANSON, R. & WAHLESTEDT, C. (1984). Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br. J. Pharmacol., 83, 519-525.
18. EDVINSSON, L., HAKANSON, R., WAHLESTEDT, C. & UDDMAN, R. (1987). Effects of neuropeptide Y on the cardiovascular system. Trends Pharmacol. Sci., 231 235.
19. FABI, F., ARGIOLAS, L., CHIAVARELLI, M. & DEL BASSO, P. (1996). Nitric oxide-dependent and -independent modulation of sympathetic vasoconstriction in the human saphenous vein. Eur. J. Pharmacol., 309, 41-50.
20. FABI, F., CHIAVARELLI, M., ARGIOLAS, L., CHIAVARELLI, R & DEL BASSO, P. (1993). Evidence for sympathetic neurotransmission through presynaptic N-type calcium channels in human saphenous vein. Br. J. Pharmacol., 110, 338 342.
21. FURCHGOTT, R.F. & VANHOUTTE, P.M. (1989). Endothelium-derived relaxing and contracting factors. FASEB J., 3, 2007 2018.
22. GUSTAFSSON, H. & NILSSON, H. (1990). Endothelium-independent potentiation by neuropeptide Y of vasoconstrictor responses in isolated arteries from rat and rabbit. Acta Physiol. Scand., 138, 503 507.
23. HIEBLE, J.P., DUESLER, J.G. & DALY, R.N. (1989). Effects of neuropeptide Y on the response of isolated blood vessels to norepincphrine and sympathetic field stimulation. J. Pharmacol. Exp. Ther., 250, 523 528.
24. INOUE, A., YANAGISAWA, M., KIMURA, S., KASUYA, Y., MIYAUCHI, T., GOTO, K. & MASAKI, T. (1989). The human endothelin family: three structurally and pharmacologically distinet isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A., 86, 2863 2867.
25. KATUSIC, Z.S., SHEPHERD, J.T. & VANHOUTTE., P.M. (1988). Endothelium-dependent contractions to calcium ionophore A23187, arachidonic acid and acetylcholine in canine basilar arteries. Stroke, 19, 476 479.
26. LI. K., SIROIS, P. & ROULEAU, J.L. (1994). Role of endothelial cells in cardiovascular function. Life Sci., 54, 579 592.
27. 2: an endothelium-derived vasoconstrictor in human internal mammary arteries. Ann. Thorac. Surg., 56, 97 100.
28. LUNDBERG, J.M., HEMSEN, A., LARSSON, O., RUDEHILL, A., SARIA, A & FREDHOLM, B.B. (1988). Neuropeptide Y receptor in pig spleen: binding characteristics, reduction of cyclic AMP formation and calcium inhibition of vasoconstriction. Eur. J. Pharmacol., 145, 21 30.
29. LUU, T.N., CHESTER, A.H., O'NEIL, G.S., TADJKARIMI, S. & YACOUB, M.H. (1992). Effects of vasoactive neuropeptides on human saphenous vein. Br. Heart J., 67, 474 477.
30. MACHO, P., PEREZ, R., HUIDOBRO-TORO, J.P. & DOMENECH, R.J. (1989). Neuropeptide Y (NPY): a coronary vasoconstrictor and potentiator of catecholamine-induced coronary constriction. Eur. J. Pharmacol., 167, 67 74.
31. 2 receptors and involvement of eicosanoids. Br. J. Pharmacol., 120, 215 220.
32. 2 receptor antagonist on airway smooth muscle in vitro. Br. J. Pharmacol., 104, 585 590.
33. NOREL, X., LABAT, C., GARDINER, P.J. & BRINK, C. (1991). Inhibitory effects of Bay u3405 on prostanoid-induced contractions in human isolated bronchial and pulmonary arterial muscle preparations. Br. J. Pharmacol., 104, 591 595.
34. OELLERICH, W.F. & MALIK, K.U. (1993). Neuropeptide Y modulates the vascular response to periarterial nerve stimulation primarily by a postjunctional action in the isolated perfused rat kidney. J. Pharmacol. Exp. Ther., 266, 1321 1329.
35. 2/prostagiandin endoperoxide receptor antagonist. J. Pharmacol. Exp. Ther., 264, 570 578.
36. PARRY, M.J., RANDALL, M.J., HAWKESWOOD, E., CROSS, P.E., & DICKINSON, R.P. (1982). Enhanced production of prostacyclin in blood after treatment with selective thromboxane synthetase inhibitor, UK-38,484. Br. J. Pharmacol., 75, Suppl., 547 P.
37. PERNOW, J., SARIA, A. & LUNDBERG, J.M. (1986). Mechanisms underlying pre- and postjunctional effects of neuropeptide Y in sympathetic vascular control. Acta Physiol. Scand., 126, 239 249.
38. POTTER, E.K. (1988). Neuropeptide Y as an autonomic neurotransmitter. Pharmacol. Ther., 37, 251 273.
39. PRIETO, D., SIMONSEN, U. & NYBORG, N.C.B. (1995). Regional involvement of an endothelium-derived contractile factor in the vasoactive actions of neuropeptide Y in bovine isolated retinal arteries. Br. J. Pharmacol., 116, 2729 2737.
40. SAVILLE, V.L., MAYNARD, K.I. & BURNSTOCK, G. (1990). Neuropeptide Y potentiates purinergic as well as adrenergic responses of the rabbit ear artery. Eur. J. Pharmacol., 176, 117 125.
41. SMALL, D.L., BOLZON, B.J. & CHEUNG, D.W. (1992). Endothelium-independent potentiating effects of neuropeptide Y in the rat tail artery. Eur. J. Pharmacol., 210, 131 136.
42. VANHOUTTE, P.M., LUSCHER, T.F. & GRASER, T. (1991). Endothelium-dependent contractions. Blood Vessels, 28, 74 83
43. VU, H.Q., BUDAI, D. & DUCKLES, S.P. (1989). Neuropeptide Y preferentially potentiates responses to adrenergic nerve stimulation by increasing rate of contraction. J. Pharmacol. Exp. Ther., 251, 852 857.
44. WAHLENSTEDT, C., EDVINSSON, L., EKBLAD, E. & HAKANSON, R. (1985). Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J. Pharmacol. Exp. Ther., 234, 735 741.
45. WESTFALL, T.C., YANG, C.I., & CURFMAN-FALVEY, M. (1995). Neuropeptide Y-ATP interactions at the vascular sympathetic neuroeffector junction. J. Cardiovasc. Pharmacol., 26, 682 687.
46. WINER, B.J. (1971). Statistical Principles In Experimental Design. 514 603. New York: McGraw-Hill Book Company.
47. WONG-DUSTING, H.J. & RAND, M.J. (1988). Pre- and postjunctional effects of neuropeptide Y on the rabbit isolated ear artery. Clin. Exp. Pharmacol. Physiol., 15, 411 418.
48. YANAGISAWA, M., KURIHARA, H., KUMURA, S., TOMOBE, Y., KOBAYASHI, M., MITSUI, T., YASAKI, Y., GOTO, K. & MASAKI, T. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332, 411 415.
49. YANG, Z., RICHARD, V., VON SEGESSER, L., BAUER, E., STULZ, P., TURINA, M. & LUSCHER, F. (1990). Threshold concentrations of endolhelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. Circulation. 82, 188 195.
50. YANG, Z., VON SEGESSER, L., BAUER, E., STULZ, P., TURINA, M. & LUSCHER, T.F. (1991). Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ. Res., 68, 52 60.